Development of anti-MDA5 autoantibody-positive dermatomyositis following the use of etanercept biosimilar in rheumatoid arthritis.
Soshi OkazakiTsuyoshi ShiraiHiroko SatoTomonori IshiiHiroshi FujiiPublished in: Modern rheumatology case reports (2024)
The induction of autoimmune diseases during tumour necrosis factor-alpha inhibitor (TNFi) usage has been described. Herein, we report a rare case of a 49-year-old woman with antimelanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM), which developed 5 weeks after the introduction of an etanercept biosimilar to rheumatoid arthritis (RA). Four of the five known cases, including ours, of anti-MDA5Ab-positive DM complicated with RA revealed anti-MDA5Ab-positive DM following TNFi usage. When patients with RA are diagnosed with interstitial lung disease during TNFi usage, anti-MDA5 Ab-positive DM could be a differential diagnosis.
Keyphrases
- rheumatoid arthritis
- interstitial lung disease
- disease activity
- systemic sclerosis
- breast cancer cells
- ankylosing spondylitis
- rheumatoid arthritis patients
- idiopathic pulmonary fibrosis
- rare case
- cell cycle arrest
- juvenile idiopathic arthritis
- glycemic control
- systemic lupus erythematosus
- copy number
- type diabetes
- genome wide
- dna methylation
- adipose tissue
- cell death
- transcription factor
- single cell
- preterm birth